Enveric Biosciences (ENVB) EPS (Basic) Growth (3y) (2013 - 2026)
Enveric Biosciences (ENVB) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | -38.31% |
| 10 | Enveric Biosciences | 5.50 Mn | -2.79 Mn | - | 88.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.25% |
| Dec 31, 2025 | 77.75% |
| Sep 30, 2025 | 65.45% |
| Jun 30, 2025 | 71.26% |
| Mar 31, 2025 | 75.24% |
| Dec 31, 2024 | 83.26% |
| Sep 30, 2024 | 65.56% |
| Jun 30, 2024 | 51.18% |
| Mar 31, 2024 | 70.03% |
| Dec 31, 2023 | 58.48% |
| Sep 30, 2023 | 68.18% |
| Jun 30, 2023 | 68.30% |
| Mar 31, 2023 | 73.16% |
| Dec 31, 2022 | 70.96% |
| Sep 30, 2022 | 37.84% |
| Jun 30, 2022 | 72.78% |
| Mar 31, 2022 | 70.97% |
| Dec 31, 2021 | 72.41% |
| Sep 30, 2021 | -26.13% |
| Jun 30, 2021 | 81.93% |